{"id":"W2621281002","doi":"10.1182/blood.v128.22.4526.4526","title":"Biomarker Driven Phase II Clinical Trial of Trametinib in Relapsed/Refractory Multiple Myeloma with Sequential Addition of the AKT Inhibitor, GSK2141795 at Time of Disease Progression to Overcome Treatment Failure: A Trial of the Princess Margaret Phase II Consortium","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; University Health Network; Queen's University; University of Calgary; Princess Margaret Cancer Centre","funders":"","keywords":"Trametinib; Neuroblastoma RAS viral oncogene homolog; Medicine; Protein kinase B; Multiple myeloma; Progressive disease; Oncology; Biomarker; Internal medicine; Clinical trial; PI3K/AKT/mTOR pathway; Lenalidomide; MEK inhibitor; Cancer research; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; MAPK/ERK pathway; Cancer; Disease; Biology; KRAS; Signal transduction","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001815372,0.001285418,0.001385584,0.0003850858,0.0004176799,0.0009322491,0.0009286308,0.001384004,0.003455352],"category_scores_gemma":[0.0006068896,0.0005343242,0.001114906,0.0003839321,0.0006083701,0.0007073703,0.0003232937,0.002775363,0.0007285043],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009866077,"about_ca_system_score_gemma":0.00182931,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001070729,"about_ca_topic_score_gemma":0.003074714,"domain_scores_codex":[0.9996457,0.0001748641,0.00001711928,0.00005186756,0.00003552872,0.00007483301],"domain_scores_gemma":[0.9995678,0.0000478999,0.00007957385,0.00003308961,0.00003536851,0.0002361528],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7734042,0.05418969,0.006573749,0.0009054564,0.001678428,0.0002859046,0.0002446561,0.003368354,0.06383657,0.0004334826,0.00680631,0.08827322],"study_design_scores_gemma":[0.6558955,0.3253776,0.009626959,0.00003180311,0.0003442025,0.0002289322,0.00003424356,0.00152516,0.004635388,0.0001801207,0.002094997,0.00002508138],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924517,0.001294775,0.0003487175,0.0006273342,0.00008513225,0.002610773,0.001064464,0.00008238485,0.001434569],"genre_scores_gemma":[0.9884297,0.001137099,0.001427783,0.0008394842,0.0001122496,0.00310024,0.001987372,0.00002129232,0.002944663],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003455352,"threshold_uncertainty_score":0.01155925,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04344315609987847,"score_gpt":0.362560811938252,"score_spread":0.3191176558383735,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}